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Key Questions  
What is already known on this subject?  
• Marked excess alcohol consumption (>80g/day for 5 years) is associated with 
alcoholic cardiomyopathy.  
• The effects of moderate excess alcohol consumption on cardiac structure and 
function is not known.  
• There is no clear evidence base to guide lifestyle advice on alcohol 
consumption for patients with dilated cardiomyopathy.  
 
What is new?  
• Patients with dilated cardiomyopathy who have a history of moderate excess 
alcohol consumption (>14 units/week for women, >21 units/week for men) have 
increased biventricular dilatation and biventricular impairment as well as left 
atrial dilation and more hypertrophy compared to patients without moderate 
excess alcohol consumption.  
• After adjusting for biological sex, moderate alcohol excess was not associated 
with adverse cardiac structure suggesting that lifestyle factors such as 
moderate excess alcohol use may contribute to the sex-specific differences in 
cardiac structure in dilated cardiomyopathy.  
• This study did not find either a beneficial or large adverse effect on 
cardiovascular outcomes.  
 
How might this impact on clinical practice?  
 
• The alcohol consumption by patients in this study was well below the 
threshold for alcoholic cardiomyopathy. This study suggests that particularly 
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for men with dilated cardiomyopathy, even moderate alcohol excess is 
associated with adverse cardiac structure and function. 







The effect of moderate excess alcohol consumption is widely debated and has not 
been well defined in dilated cardiomyopathy (DCM). There is need for a greater 
evidence base to help advise patients. We sought to evaluate the effect of moderate 




Prospective longitudinal observational cohort study. Patients with DCM (n=604) were 
evaluated for a history of moderate excess alcohol consumption (UK government 
guidelines; >14 units/week for women, >21 units/week for men) at cohort enrollment, 
had cardiovascular magnetic resonance and were followed up for the composite 
endpoint of cardiovascular death, heart failure and arrhythmic events. Patients 
meeting criteria for alcoholic cardiomyopathy were not recruited.  
 
Results 
DCM patients with a history of moderate excess alcohol consumption (n=98, 16%) 
had lower biventricular function and increased chamber dilatation of the left ventricle, 
right ventricle and left atrium, as well as increased left ventricular hypertrophy 
compared to patients without moderate alcohol consumption. They were more likely 
to be male (alcohol excess group– n =92, 94% vs n =306, 61%, p=<0.001). After 
adjustment for biological sex, moderate excess alcohol was not associated with 
adverse cardiac structure. There was no difference in mid-wall myocardial fibrosis 
between groups. Prior moderate excess alcohol consumption did not affect prognosis 
(HR 1.29, 0.73 to 2.26, p=0.38) during median follow up of 3.9 years.  
 
Conclusion 
Dilated cardiomyopathy patients with moderate excess alcohol consumption have 
adverse cardiac structure and function at presentation but this is largely due to 
biological sex. Alcohol may contribute to sex-specific phenotypic differences in 





Alcohol, heart, prognosis  
 
Abbreviations: 
CMR; cardiovascular magnetic resonance 
DCM; dilated cardiomyopathy  
HR; hazard ratio 
ICD; implantable cardiac defibrillator  
LGE; late gadolinium enhancement  





The effect of moderate alcohol consumption is widely debated and has not been well 
defined in dilated cardiomyopathy (DCM). From a global health perspective, there 
has been increased recent interest in the effects of alcohol on the heart, particularly 
the potentially beneficial effects of low to moderate alcohol consumption on 
cardiovascular disease1. Studies indicate that modest alcohol consumption may be 
associated with a lower risk for heart failure 2. However, Mendelian methodological 
approaches have raised doubts regarding the cardioprotective effects of low to 
moderate alcohol consumption3. Guidance on alcohol consumption is frequently 
requested by patients with no clear evidence base to advise patients.  
 
It is established that chronic excess alcohol consumption can lead to an alcoholic 
cardiomyopathy with adverse outcomes4. However the effect of a prior history of 
moderate excess alcohol consumption remains an important unanswered question for 
clinicians and patients.  
 
In this study, our aim was to determine the effects of a history of moderate excess 
alcohol consumption on cardiovascular structure, function and outcomes in a well 
characterised cohort of patients with dilated cardiomyopathy.  Notably, no patients 




The data and analysis methods that support the findings of this study are available 
from the corresponding author, (UT), upon reasonable request. Data will be shared 
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after review and approval by our Biobank scientific board and terms of collaboration 
will be reached together with a signed data access agreement. 
 
Study population  
The study population comprised 604 patients with dilated cardiomyopathy confirmed 
by late gadolinium enhancement cardiovascular magnetic resonance prospectively 
enrolled in the National Institute for Health Research Royal Brompton Hospital 
Cardiovascular Biobank project between 2009-2015. Patients were recruited from a 
network of >30 regional hospitals. No patients with a diagnosis of alcoholic 
cardiomyopathy were recruited (alcohol consumption in excess of 80g/day for 5 
years.5) Patients were enrolled at the time of the first diagnostic imaging study. All 
patients underwent baseline clinical evaluation, ECG, genetic assessment, and CMR 
including evaluation for late gadolinium enhancement mid wall fibrosis as previously 
described6.  Socio-economic status was assessed using the Index of Multiple 
Deprivation quintile. All patients provided written informed consent. The study was 
approved by the regional ethics committee. 
 
DCM was diagnosed based on established CMR criteria of left ventricular dilation 
and reduced ejection fraction with reference to age and gender adjusted nomograms7 
in the absence of known coronary artery disease (presence of subendocardial late 
gadolinium enhancement (LGE) suggestive of previous myocardial infarction, >50% 
stenosis in one or more major epicardial coronary arteries, or need for previous 
percutaneous coronary intervention or coronary artery bypass grafting), abnormal 
loading conditions (uncontrolled hypertension or significant primary valvular 
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disease), acute myocarditis, or non-alcohol toxin exposure. A history of well-
controlled hypertension or diabetes was documented as comorbidities.  
 
Alcohol history  
Alcohol consumption prior to the diagnosis of dilated cardiomyopathy was assessed by 
patient interview and review of medical records. Patient interview using a standardised 
questionnaire was conducted by a research nurse at study enrollment and patients’ 
current weekly alcohol consumption as well as previous alcohol history were recorded. 
The hospital and primary care medical records were reviewed by the study investigators 
for any evidence of documented alcohol consumption greater than the threshold for 
moderate excess (Table 1). Both sources of data (patient reported and medical records) 
were used to classify patients. Moderate ‘alcohol excess’ was defined as a binary 
variable indicating a history of consumption greater than 21 units/week for men and 14 
units/week for women (1 unit of alcohol = 10 mL or 8 g of pure alcohol, an amount the 
average adult metabolizes in one hour), but less than 80g/day for 5 years (the criteria 
for alcoholic cardiomyopathy). All patients had consumption well below the threshold 
for alcoholic cardiomyopathy (Supplementary Figure 1).  The 14 unit and 21 unit 
thresholds reflect ‘sensible limits’ for alcohol consumption based on UK consensus 
medical advice8 from 1987 to 2016.  
 
Self reported weekly alcohol consumption at the time of study enrollment was also 
documented and evaluated separately, although this did not form the basis of the 
primary analysis as patients with a history of moderate alcohol excess may have 
reduced consumption shortly prior to enrolment in this study; therefore current 
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consumption may not accurately reflect prior consumption. As outlined, individuals 
meeting criteria for alcoholic cardiomyopathy were not included in the cohort.  
Clinical outcomes 
The primary end-point was a composite of cardiovascular mortality, major arrhythmic 
events and major heart failure events. Cardiovascular mortality and each of the 
arrhythmic and heart failure composites were predefined secondary end-points.  
Major arrhythmic events comprised hemodynamically stable and unstable sustained 
ventricular tachycardia, ventricular fibrillation, appropriate implantable cardiac 
defibrillator (ICD) shock and aborted sudden cardiac death. Major heart failure events 
comprised heart transplantation, left ventricular assist device implantation and 
unplanned heart failure hospitalization. 
 
End-points were defined according to the 2014 American College of 
Cardiology/American Heart Association definitions for cardiovascular end-points in 
clinical trials9 and the 2006 ACC/AHA/ESC guidelines for management of patients 
with ventricular arrhythmias 10. Follow up data was collected from primary care and 
hospital medical records and patient questionnaires. Survival status was also 
identified using the UK Health and Social Care Information Service to ensure no 
deaths were missed. Death certificates and post mortem reports were obtained where 
applicable. All primary end-point events were adjudicated by an independent 
committee of 3 senior cardiologists with expertise in electrophysiology, heart failure 
management and clinical trial adjudication. They were blinded to alcohol status, 
imaging and clinical data. Follow up time was truncated at 10 years given the reduced 
number of individuals with follow up beyond 10 years. Event-free survival was 
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calculated from the date of study entry to the date of the first event in the composite 
end-point. Data for all patients who were last known to be alive, or who had died after 
December 31st 2015, were censored on December 31st 2015. 
 
Statistical methods 
Cardiac structure and function was compared between patients with and without a 
history of moderate alcohol consumption. Continuous data are expressed as median (± 
interquartile range) and compared using the Mann-Whitney test. Categorical data are 
expressed as number and percentages, and compared using Fisher’s exact test. We 
calculated unadjusted differences in cardiac phenotypes between patients with and 
without a moderate history of alcohol excess. We then calculated differences after 
using propensity scores with inverse probability weighting to adjust for differences in 
age, sex, titin truncating variants, and medication use (baseline use of beta blockers, 
ACE inhibitors, aldosterone antagonists and diuretics). We adjusted for covariates 
that we judged were likely to be associated with baseline phenotypes but unlikely to 
have been influenced by prior moderate alcohol consumption. 
 
The Kaplan–Meier method was used to estimate cumulative freedom from the end-
point, and the log-rank statistic was used to test the null hypothesis that there was no 
difference between groups in the probability of an event at any time point.  
Cox proportional hazard modelling was used to evaluate the effect of alcohol on the 
primary endpoint. An optimized baseline model predicting the primary end-point 
excluding alcohol consumption was built from all clinical, imaging and demographic 
variables using purposeful variable selection (p value threshold for inclusion was 
<0.10 for selection of variables from univariable analysis and for exclusion >0.05 for 
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exclusion of variables from multivariable analysis) and then stepwise selection 
(Supplementary methods). This consisted of left ventricular ejection fraction, left 
atrial volume, mid wall myocardial fibrosis and a prior history of ventricular 
tachycardia. As a secondary analysis, to explore a potential J shaped relationship 
between alcohol intake and cardiovascular outcomes, we calculated hazard ratios for 
the primary outcome for categories of alcohol consumption at enrollment (0-10 
units/week, 10-20 units/week, >20 units/week) relative to no alcohol consumption. 
All statistical analyses were conducted in the R environment (version 3.3.1). 
 
Patient and public involvement 
No participants were involved in setting the research question or the outcome 
measures. Patients were involved in the design and implementation of the overall 
Biobank study through participation in our Patient Advisory Groups. Results from our 
Cardiovascular Biobank cohort studies are routinely disseminated to study 
participants through our research group websites and social media outlets. We plan to 




Summary of alcohol history in cohort  
Amongst 604 DCM patients, 98 (16%) patients had a history of moderate alcohol 
excess. Their characteristics are outlined in Table 2. Patients with a history of 
moderate alcohol excess were more likely to be male but there was no significant 
difference in age between groups. There was no difference in baseline medication use, 
history of atrial fibrillation, blood pressure or symptom status at baseline (Table 2). 
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Alcohol consumption did not vary by socioeconomic status (p=0.05, Supplementary 
Table 1).  
 
Relationship between moderate excess alcohol and cardiac structure 
Dilated cardiomyopathy patients with a history of moderate excess alcohol 
consumption had a globally more impaired cardiac phenotype compared to patients 
without moderate alcohol consumption. This was characterised by lower biventricular 
function and increased chamber dilatation of the left ventricle, right ventricle and left 
atrium, as well as increased left ventricular hypertrophy (Figure 1, unadjusted 
analysis; Table 3). There was no difference in mid wall myocardial fibrosis between 
groups (late gadolinium enhancement n=43, 44% in the group with a history of 
moderate alcohol excess compared to n=170, 34% in no history of moderate excess 
alcohol group, p=0.07). These findings were not robust to adjustment for age, sex and 
clinical covariates (Table 3). Of note, restricting the analysis to males only did not 
change the results. Therefore while patients with moderate alcohol excess are likely to 
have a worse cardiac structure at presentation, this is largely due to other 
characteristics, most notably biological sex. There are two clear indicators that this 
was mostly driven by biological sex. First, sex is the only covariate that is highly 
imbalanced between those with and without moderate alcohol excess. Secondly, we 
formally checked this by adjusting for all other factors, except for sex, which made 
minimal difference to our results.  This suggests that sex specific differences in 
cardiac structure and function may be mediated by lifestyle factors such as alcohol 
consumption as 94% of the moderate alcohol excess group were male, compared to 
61% of the no alcohol excess group.  
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The effect of moderate excess alcohol consumption on cardiovascular outcomes 
Over a median follow up time of 3.9 years, 78 patients (13%) met the primary 
composite endpoint, of whom 15 patients had a history of moderate alcohol excess 
(19%) and 63 patients (81%) did not (p=0.54). The breakdown of the primary 
endpoint by event and alcohol history is listed in Supplementary Tables 2 and 3.    
 
There was no difference in freedom from the primary endpoint in DCM patients 
stratified by alcohol history (Figure 1).  There was no evidence that a history of 
moderate alcohol excess had an effect on the composite endpoint in this cohort of 
patients with DCM (HR 1.29, 0.73 to 2.26, p=0.38). Moderate alcohol excess did not 
have a detectable effect on the secondary endpoints of cardiovascular mortality: HR 
0.78 (0.23 to 2.60), p=0.68; major heart failure events: HR 0.86 (0.39 to 1.91), 
p=0.71; or major arrhythmic events: HR 2.36 (0.97 to 5.71), p=0.057. There was no 
evidence of a J-shaped relationship between alcohol intake and the primary 
cardiovascular outcome (Supplementary Figure 3).  
 
When adjusted for predefined factors known to predict outcome in this cohort (left 
ventricular ejection fraction, left atrial volume, prior history of ventricular 
tachycardia, and mid wall fibrosis)6, there was no evidence that a history of moderate 
alcohol excess was associated with the primary endpoint (Table 4). On sensitivity 
analyses, adjustment for age, sex and smoking history did not alter the study findings 
(Supplementary Table 4). 
 
At the time of study recruitment, 67 of the 98 individuals (68%) with a prior history 
of moderate alcohol excess self-reported alcohol consumption above the government 
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recommended weekly limits. Amongst these individuals with on-going moderate 
alcohol excess consumption, there was no evidence for an adverse or beneficial effect 
of ongoing moderate excess alcohol consumption on cardiovascular outcomes (HR 
for primary endpoint 1.45, 95% CI 0.76 to 2.74, p= 0.26).   
 
Definition of alcohol excess: Sensitivity analysis ESC guidelines 2016 
In 2016, the European Society of Cardiology (ESC) updated their dyslipidaemia 
guidelines outlining that moderate excess alcohol consumption (up to 20 g/day (2 
units) for men and 10 g/day (1 unit) for women) was acceptable for those who drink 
alcoholic beverages11. When DCM patients were recoded according to these limits 
based on their alcohol consumption at enrollment (moderate excess n=142, no excess 
n=462), we did not observe that moderate excess alcohol consumption was associated 
with cardiovascular outcomes (HR for moderate excess compared to no consumption 
0.94, 95% CI 0.56-1.60, p=0.83; Kaplan Meier plot in Supplementary Figure 2).  
 
Discussion  
These findings demonstrate that moderate excess alcohol consumption is associated 
with adverse cardiac structure and function in patients with dilated cardiomyopathy 
but that these differences are largely due to biological sex. Excessive alcohol 
consumption is known to be deleterious to cardiovascular health but the risks and 
benefits of low to moderate excess alcohol consumption remains an active area of 
debate. The alcohol consumption by patients in this study was well below the 
threshold for alcoholic cardiomyopathy. These findings help to inform lifestyle 
discussions for patients with dilated cardiomyopathy.  
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Whilst excessive alcohol consumption is well documented to portend adverse 
outcomes, there are much less data to guide and inform discussions with patients on 
moderate levels of consumption. This is a frequently asked question and in need of a 
greater evidence base to help advise patients. This is the first study to specifically 
evaluate the effects of a history of moderate excess alcohol consumption in dilated 
cardiomyopathy patients and the findings will be informative for both clinicians and 
patients. In our study, when adjusting for covariates including biological sex we 
found that moderate alcohol excess was not associated with adverse cardiac structure. 
This highlights the sex-specific differences in cardiac structure and function in dilated 
cardiomyopathy as well as sex-specific differences in alcohol consumption, as 94% of 
the cohort with a history of moderate alcohol excess were male compared to 61% of 
the cohort without such a history. It is plausible therefore that some of the differences 
in cardiac structure and function seen between men and women with dilated 
cardiomyopathy are driven by lifestyle factors such as moderate excess alcohol use.   
 
It is notable that despite adverse cardiac remodelling, moderate excess alcohol 
consumption was not associated with adverse outcomes. There are a number of 
possible reasons. One is that moderate excess alcohol consumption may exert a 
protective effect in terms of cardiovascular risk12,13. It is also possible that the effect 
of alcohol consumption on outcomes is mediated by an unknown or unmeasured 
confounder. Insufficient statistical power may also account for these findings however 
we would expect to see evidence of a large effect on outcome (either beneficial or 
adverse) in this cohort size, therefore this is unlikely to be the entire explanation. This 
study prompts further research to explore the reasons behind this novel finding. 
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A J- or U-shaped relationship between alcohol consumption and total mortality has 
been well documented. There has been conflicting evidence for the role of low to 
moderate excess alcohol consumption in cardiovascular disease more generally14, 15, 
and specifically with respect to heart failure phenotypes. A large study of ~6000 
individuals followed up for ~10 years in the Australian National Blood pressure study 
found no association between alcohol consumption and risk of incident heart failure 
in either men or women16. In contrast, in an Italian study of ~22,000 individuals 
followed for ~8 years, light to moderate alcohol consumption (1-4 drinks/day) was 
associated with a lower risk for heart failure, with a maximal 22% risk reduction for 
individuals consuming 20g alcohol per day13.  
 
A lack of international standardisation of alcohol intake and consensus definitions of 
low, moderate, and high consumption, makes between study comparisons more 
challenging. The WHO guidelines on alcohol define 1 standard drink to be 10g of 
pure ethanol and recommend no more than 2 standard drinks per day17 but these 
definitions are not universally adopted amongst all countries18. In addition, there is 
compelling evidence that there may not be a ‘safe’ threshold for alcohol consumption 
in terms of cardiovascular risk and cardiovascular risks may increase with alcohol 
consumption at levels lower than considered in this study19. In a pooled analysis of 
almost 600,000 individuals without cardiovascular disease, alcohol consumption 
<12.5 units/week was associated with the lowest risk of cardiovascular death. 
However, for other cardiovascular outcomes including heart failure (as well as stroke, 
coronary artery disease excluding myocardial infarction, and fatal hypertensive 
disease) there was no clear risk thresholds below which lower alcohol consumption 
stopped being associated with lower disease risk19. 
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Mid-wall fibrosis remained a strong predictor of outcome in DCM in our study, 
irrespective of history of alcohol excess. Interestingly, although there was no 
statistically significant difference in the presence of mid wall fibrosis between both 
groups, more individuals with a history of higher alcohol consumption had mid wall 
fibrosis compared to individuals without a history of alcohol excess. In contrast, a 
previous CMR study of 165 light to moderate drinkers without pre-existing cardiac 
disease suggested that these individuals had less diffuse myocardial fibrosis (lower T1 
times) compared to non drinking controls20. The differences may be due to the 
presence of overt cardiomyopathy in this cohort. 
 
There are some potential limitations to this analysis. With regards to current alcohol 
consumption, we only have the data recorded at one time point at study recruitment 
and do not know how patients’ consumption may have changed over the time course 
of the study follow up. This may have affected the outcome in a time varying manner 
which is not accounted for in the current study design. In real world settings however, 
guidance is similarly based on reported consumption, so this study takes a pragmatic 
approach. The effect of ongoing consumption should be addressed in future 
prospective studies. In addition, although all the analyses suggest that it is unlikely 
that alcohol use is associated with a much lower risk of adverse cardiovascular 
outcomes, we cannot definitively exclude that consumption within guideline limits is 
not protective or that that the risk of moderate excess alcohol consumption is not 
increased in the current sample size and follow up period. Finally, the majority of 
studies evaluating alcohol and cardiovascular health are observational, including this 
one, and despite optimal study design and statistical analysis they are subject to the 
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effect of confounders. Due to ethical considerations, randomised controlled trials in 
this area are limited, although one is currently in progress (Moderate Alcohol and 
Cardiovascular Health Trial; NCT03169530). Globally, alcohol consumption is an 
established risk factor for many chronic diseases and contributes to an increase in 
disease burden.  
 
Conclusion 
Excessive alcohol consumption is known to be deleterious to cardiovascular health 
but the risks and benefits of low to moderate alcohol consumption remains an active 
area of debate. We demonstrate that moderate excess alcohol consumption is 
associated with adverse cardiac structure and function in patients with DCM, though 
this was driven by the preponderance of men in the alcohol excess group suggesting 
that sex specific differences in cardiac structure in DCM may be driven by lifestyle 
factors such as alcohol use. This study adds to the growing body of evidence refuting 
a substantial cardioprotective effect of moderate alcohol consumption. We were 
unable to detect a large beneficial or large adverse effect on medium term outcomes. 
Larger studies are needed to evaluate for potentially safe or harmful thresholds of 
alcohol consumption amongst patients with DCM.  
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Figure 1: Box plots demonstrating variations in cardiac structure and function in patients with 
dilated cardiomyopathy stratified by previous alcohol intake. Patients with a history of moderate 
alcohol excess have lower biventricular function (left and right ventricular ejection fraction, 
LV/RVEF) and more dilated ventricles (left and right ventricular end diastolic volume, 
LV/RVEDVi; left and right ventricular end systolic volume, LV/RVESVi), as well as increased 
left ventricular mass (LVMi) and dilated left atria (left atrial volume, LAVi). These differences 
were not robust to adjustment for age, sex and clinical covariates (titin truncating variant status, 
medication use including beta blockers, ACE inhibitors, aldosterone antagonists, and diuretics). 
Adjusted p values shown.  
 
Figure 2: Kaplan Meier survival curve showing freedom from primary endpoint (composite of 
cardiovascular death, heart failure events, and arrhythmic events) in DCM patients stratified by 










Table 1: Definitions of alcohol consumption and moderate alcohol excess in the UK, Europe and 
North America 
Diagnosis  Alcohol 
consumption  
Used in this study  Notes 
Alcoholic 
cardiomyopathy  
80g/day for at 
least 5 years  
No patients with alcoholic 
cardiomyopathy were 
recruited to this study  
- 
Moderate alcohol 










Yes – the basis of the 
primary analysis  
UK 1 unit of alcohol = 
10 mL or 8 g of pure 
alcohol, an amount the 
average adult 
metabolizes in one hour 
Moderate alcohol 
excess according to 
the European Society 
of Cardiology 2016  
Men: Up to 
20g/day (2 units) 
Women: up to 
10g/day (1 unit)  
Considered in secondary 
sensitivity analysis; not the 
basis of the primary 
analysis 
ESC 1 unit of alcohol = 
10g alcohol  
Moderate alcohol 
excess according to 
the United States 
Centre for Disease 
Control/US Dietary 
Guidelines  






No  US ‘standard drink’ = 
∼12 g alcohol 
Moderate alcohol 
excess according to 




No WHO ‘standard drink’ = 
10g alcohol  
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Table 2: Summary of demographics in cohort stratified by alcohol status. Data are shown as 
median (interquartile range) or numbers (percentages) and compared using the Mann Whitney test or 
Fisher’s exact test as appropriate. Moderate alcohol excess is defined as per Table 1. No alcohol excess 
is defined as consumption below these limits including no consumption at all.  
 No alcohol excess 
(n=506) 
Moderate alcohol excess 
(n=98) 
p 
Demographics and comorbidities  
Age  53.9 (44.0, 64.9)  54.9 (46.7, 60.6)  0.99 
Sex = Male (%)    306 (60.5)      92 (93.9)  <0.001 
Caucasian = Yes (%)    431 (85.2)      93 (94.9)   0.015 
LBBB = Yes (%)    142 (28.1)      22 (22.4)   0.31 
Hypertension = Yes (%)    152 (30.0)      28 (28.6)   0.87 
Systolic blood pressure 
(mmHg) 
120 (108, 134) 122 (111, 135) 0.57 
Diastolic blood pressure 
(mmHg) 
71 (62, 81) 75 (66, 83) 0.05 
Atrial fibrillation =Yes (%) 123 (24.3) 27 (27.6) 0.52 
Diabetes mellitus = Yes 
(%) 
    66 (13.0)       5 (5.1)   0.039 
NYHA class(%)           0.49 
   I    205 (42.8)      47 (49.5)   
   II    196 (40.9)      34 (35.8)   
   III/IV     78 (16.3)      14 (14.7)   
Medications  
Diuretics = Yes (%)    224 (44.3)      46 (46.9)   0.71 
26 
Beta blocker = Yes (%)    353 (69.8)      72 (73.5)   0.54 
ACE inhibitor = Yes (%)    399 (78.9)      79 (80.6)   0.80 
Aldosterone antagonist= 
Yes (%) 
   181 (35.8)      37 (37.8)   0.80 
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Table 3: Unadjusted and adjusted analyses of the relationship between moderate alcohol excess 
and cardiac structure and function. Adjusted analyses covariates: age, sex, titin truncating variant 
status, medication use including beta blockers, ACE inhibitors, aldosterone antagonists, and diuretics.  
 
 
Unadjusted analysis Adjusted analysis  









Indexed left atrial volume 
(ml/m2) 
5.9 (0.4 to 
11.5) 
0.035 3.0 (-3.7 to 9.7) 0.38 
Indexed left ventricular end 
diastolic volume (ml/m2) 
8.3 (0.1 to 
16.4) 
0.048 4.3 (-4.6 to 
13.2) 
0.34 
Left ventricular ejection 
fraction (%) -3.3 (-6.0 to -
0.6) 
0.017 
-3.2 (-7.3 to 1.0) 
0.13 
28 
Indexed left ventricular end 
systolic volume (ml/m2) 
9.4 (1.0 to 
17.9) 
0.028 6.7 (-3.6 to 
17.0) 
0.20 
Indexed left ventricular 
mass (g/m2) 
6.6 (1.5 to 
11.7) 
0.012 2.4 (-5.5 to 
10.2) 
0.55 
Indexed right ventricular 
end diastolic volume 
(ml/m2) 
5.4 (0.4 to 
10.4) 
0.034 -1.0 (-7.5 to 5.5) 0.76 
Right ventricular ejection 
fraction (%) 
-4.9 (-7.8 to -
2.0) 
0.0010 -2.7 (-7.3 to 1.9) 0.25 
Indexed right ventricular 
end systolic volume (ml/m2) 
6.8 (2.3 to 
11.3) 
0.0030 






Table 4: Adjusted hazard ratio for primary composite endpoint evaluating the association 
between prior alcohol consumption and major cardiovascular outcomes in the study cohort 
(n=604).  *No alcohol excess includes patients with no alcohol consumption and consumption 
within guideline limits.  
 HR (95%CI) P 
Indexed left atrial volume (per 10mL/m2) 1.12 (1.07-
1.17) 
0.000004 
Presence of mid wall fibrosis  2.33 (1.44-
3.76) 
0.0006 
Left ventricular ejection fraction (per 10%) 0.7 (0.58-
0.84) 
0.0002 
Prior history of sustained VT 3.21 (1.26-
8.18) 
0.01 
Moderate alcohol excess prior to recruitment compared to no 
alcohol excess*  
1.02 (0.57-
1.84) 
0.94 
 
